NCT03542994View on ClinicalTrials.gov

A Study of EDP1066 in Healthy Participants and Participants With Mild to Moderate Psoriasis and Atopic Dermatitis

PHASE1CompletedINTERVENTIONAL
Enrollment

114

Participants

Timeline

Start Date

April 24, 2019

Primary Completion Date

January 3, 2020

Study Completion Date

January 3, 2020

Conditions
PsoriasisAtopic Dermatitis
Interventions
OTHER

EDP1066

EDP1066 is an orally administered monoclonal microbial

DRUG

Placebo oral capsule

placebo

Trial Locations (7)

GU2 7XP

University of Surrey Clinical Research Center, Guildford

S75 3DL

MAC Clinical Research, Barnsley

WS11 0BN

MAC Clinical Research, Cannock

L78XP

Royal Liverpool Clinical Research Unit, Liverpool

M13 9NQ

MAC Clinical Research, Manchester

M23 9QZ

Medicines Evaluation Unit Ltd., The Langley Building, Wythenshawe Hospital, Manchester

TS17 6EW

MAC Clinical Research, Stockton-on-Tees

Sponsors
All Listed Sponsors
lead

Evelo Biosciences, Inc.

INDUSTRY

NCT03542994 - A Study of EDP1066 in Healthy Participants and Participants With Mild to Moderate Psoriasis and Atopic Dermatitis | Biotech Hunter | Biotech Hunter